We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

6 hedge funds and large institutions have $1.86M invested in Loncar China BioPharma ETF in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

195% more capital invested

Capital invested by funds: $631K → $1.86M (+$1.23M)

50% more funds holding

Funds holding: 4 → 6 (+2)

9.17% more ownership

Funds ownership: 3.32% → 12.48% (+9.2%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$1.5M
2
UBS Group
UBS Group
Switzerland
+$38.9K
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$41

Top Sellers

Rank Fund Capital Flow
1
FEM
Fulcrum Equity Management
Texas
-$25.6K
2
MCM
MV Capital Management
Maryland
-$19K
3
Osaic Holdings
Osaic Holdings
Arizona
-$3.75K

CHNA Hedge Fund Activity: Q3 2021 in Review

6 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2021, worth a combined $1.86M — up 195% from $631K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CHNA positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $1.5M. The largest seller was Fulcrum Equity Management, cutting an estimated $25.6K.

  • 6 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2021, up from 4 in Q2 2021.
  • Funds reported $1.86M of Loncar China BioPharma ETF stock for Q3 2021, up 195% quarter-over-quarter.
  • 3 funds opened new Loncar China BioPharma ETF positions in Q3 2021 and 1 closed out, a net change of +2 holders.
  • The largest Loncar China BioPharma ETF buyer in Q3 2021 was Jane Street, an estimated $1.5M added.
  • The largest Loncar China BioPharma ETF seller in Q3 2021 was Fulcrum Equity Management, an estimated $25.6K sold.

Based on aggregated 13F filings for Q3 2021.